<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000138713123003545/admp-8k_031622.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000138713123003545/0001387131-23-003545-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 7.01 Item 9.01

Adamis Pharmaceuticals Corp

Announcement: ADMP 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000138713123003527/admp-8k_031622.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000138713123003527/0001387131-23-003527-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 2.02 Item 9.01

Analyst Summary: Adamis Pharmaceuticals Corporation has released its financial results for the year ended Dec 31, 2022, indicating a net loss of $28.2M or $(0.24) per share, as compared to the net loss of $24.7 million or $(0.23) per share, for the year ended Dec 31, 2021. The biopharmaceutical company announced the signing of a merger agreement with DMK Pharmaceuticals, which is subject to approval by the company's stockholders. As of Feb 23, 2023, Nasdaq granted Adamis' request to extend the compliance period to regain compliance with a $1 minimum bid share price requirement. Adamis' products approved by the FDA include ZIMHI® Injection for the treatment of opioid overdose and SYMJEPI® Injection for use in the emergency treatment of acute allergic reactions. The CEO of Adamis Pharmaceuticals stated: "We continue to focus on our ongoing efforts to drive value for our investors, including executing on our recent merger with DMK Pharmaceuticals, which we believe has strong potential to drive even stronger growth for the company." However, the company stated that if it does not obtain required additional equity or debt funding, its cash resources will be depleted, potentially requiring the company to seek bankruptcy protection or other alternatives to resolve its obligations and liabilities that could result in its stockholders losing their investment in the company.

$ADMP reports FY2022 results & merger agreement with DMK Pharmaceuticals

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000138713123003523/admp-10k_123122.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000138713123003523/0001387131-23-003523-index.htm>Original filing index</a>
                    </div>

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

CONSENT OF BDO USA, LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

CERTIFICATION BY CEO PURSUANT TO SECTION 302

CERTIFICATION BY CFO PURSUANT TO SECTION 302

CERTIFICATION BY CEO PURSUANT TO SECTION 906

CERTIFICATION BY CFO PURSUANT TO SECTION 906

Error: Cannot read properties of null (reading '1')

Announcement: ADMP 10-K Annual Report

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000183988223006682/admp-8k_022523.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000183988223006682/0001839882-23-006682-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 8-K - Current report - Item 1.01 Item 9.01

FORM OF PREFUNDED COMMON STOCK PURCHASE WARRANT

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000183988223004980/admp-8k_022423.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000183988223004980/0001839882-23-004980-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 1.01 Item 3.02 Item 5.02 Item 7.01 Item 9.01

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000138713123002294/admp-8k_022123.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/887247/000138713123002294/0001387131-23-002294-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 3.01 Item 7.01 Item 9.01